{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T01:28:21Z","timestamp":1790040501001,"version":"4.0.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1124\/jpet.116.232066","type":"journal-article","created":{"date-parts":[[2016,2,24]],"date-time":"2016-02-24T04:39:01Z","timestamp":1456288741000},"page":"382-393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":114,"title":["Coproporphyrins I and III as Functional Markers of OATP1B Activity: In Vitro and In Vivo Evaluation in Preclinical Species"],"prefix":"10.1016","volume":"357","author":[{"given":"Hong","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongtong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaofeng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Freeden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingru","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Griffith","family":"Humphreys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Punit","family":"Marathe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yurong","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.116.232066_bib1","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1124\/dmd.110.032268","article-title":"Cyclosporine A, but not tacrolimus, shows relevant inhibition of organic anion-transporting protein 1B1-mediated transport of atorvastatin","volume":"38","author":"Amundsen","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.116.232066_bib2","first-page":"585","article-title":"Studies of coproporphyrin. VII. Adaptation of the Eriksen paper chromatographic method to the quantitative analysis of the isomers in normal human urine","volume":"63","author":"Aziz","year":"1964","journal-title":"J Lab Clin Med"},{"key":"10.1124\/jpet.116.232066_bib3","first-page":"596","article-title":"Studies of coproporphyrin. VIII. Reinvestigation of the isomer distribution in jaundice and liver diseases","volume":"63","author":"Aziz","year":"1964","journal-title":"J Lab Clin Med"},{"key":"10.1124\/jpet.116.232066_bib4","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/0009-8981(69)90083-7","article-title":"An analysis of the porphyrins of normal and cirrhotic human liver and normal bile","volume":"26","author":"Aziz","year":"1969","journal-title":"Clin Chim Acta"},{"key":"10.1124\/jpet.116.232066_bib5","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3109\/00498254.2015.1085111","article-title":"Organic anion transporting polypeptide (OATP)-mediated transport of coproporphyrins I and III","volume":"46","author":"Bednarczyk","year":"2016","journal-title":"Xenobiotica"},{"key":"10.1124\/jpet.116.232066_bib6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1042\/cs0400017","article-title":"Abnormal excretion of the isomers of urinary coproporphyrin by patients with Dubin-Johnson syndrome in Israel","volume":"40","author":"Ben-Ezzer","year":"1971","journal-title":"Clin Sci"},{"key":"10.1124\/jpet.116.232066_bib7","first-page":"498757","article-title":"Urinary elimination of coproporphyrins is dependent on ABCC2 polymorphisms and represents a potential biomarker of MRP2 activity in humans","volume":"2011","author":"Benz-de Bretagne","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"10.1124\/jpet.116.232066_bib8","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s40262-014-0222-6","article-title":"Characterization of the transmembrane transport and absolute bioavailability of the HCV protease inhibitor danoprevir","volume":"54","author":"Brennan","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/jpet.116.232066_bib9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cbi.2009.06.010","article-title":"Interaction of porphyrins with human organic anion transporting polypeptide 1B1","volume":"182","author":"Campbell","year":"2009","journal-title":"Chem Biol Interact"},{"key":"10.1124\/jpet.116.232066_bib10","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2003.08.049","article-title":"Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fuorouracil-refractory metastatic colon cancer","volume":"21","author":"Chester","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1124\/jpet.116.232066_bib11","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1124\/dmd.115.063347","article-title":"Evaluation of cynomolgus monkeys for the identification of endogenous biomarkers for hepatic transporter inhibition and as a translatable model to predict pharmacokinetic interactions with statins in humans","volume":"43","author":"Chu","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.116.232066_bib12","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/jcph.442","article-title":"Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline","volume":"55","author":"Davenport","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/jpet.116.232066_bib13","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1023\/A:1018943613122","article-title":"Physiological parameters in laboratory animals and humans","volume":"10","author":"Davies","year":"1993","journal-title":"Pharm Res"},{"key":"10.1124\/jpet.116.232066_bib14","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1124\/mol.112.084152","article-title":"Structure-based identification of OATP1B1\/3 inhibitors","volume":"83","author":"De Bruyn","year":"2013","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.116.232066_bib15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2125.2010.03773.x","article-title":"4\u03b2-Hydroxycholesterol, an endogenous marker of CYP3A4\/5 activity in humans","volume":"71","author":"Diczfalusy","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/jpet.116.232066_bib16","first-page":"147","article-title":"Diagnostic and pathogenetic implications of urinary coproporphyrin excretion in the Dubin-Johnson syndrome","volume":"37","author":"Frank","year":"1990","journal-title":"Hepatogastroenterology"},{"key":"10.1124\/jpet.116.232066_bib17","first-page":"337","article-title":"Ether-soluble porphyrins in bile, meconium and urine: a new appraisal by microscale counter-current analysis","volume":"31","author":"French","year":"1966","journal-title":"Clin Sci"},{"key":"10.1124\/jpet.116.232066_bib18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000185945","article-title":"Plasma porphyrins in chronic renal failure","volume":"55","author":"Gebril","year":"1990","journal-title":"Nephron"},{"key":"10.1124\/jpet.116.232066_bib19","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.mam.2012.10.009","article-title":"The SLCO (former SLC21) superfamily of transporters","volume":"34","author":"Hagenbuch","year":"2013","journal-title":"Mol Aspects Med"},{"key":"10.1124\/jpet.116.232066_bib20","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1093\/clinchem\/45.7.1070","article-title":"Plasma porphyrins in the porphyrias","volume":"45","author":"Hindmarsh","year":"1999","journal-title":"Clin Chem"},{"key":"10.1124\/jpet.116.232066_bib21","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1001\/archderm.139.10.1373","article-title":"Cyclosporine-induced pseudoporphyria","volume":"139","author":"Hivnor","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1124\/jpet.116.232066_bib22","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1517\/17425250902976854","article-title":"Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs","volume":"5","author":"Ieiri","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/jpet.116.232066_bib23","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1124\/dmd.113.055475","article-title":"6\u03b2-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3\/SLC22A8, in healthy subjects","volume":"42","author":"Imamura","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.116.232066_bib24","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/clpt.2012.138","article-title":"N-methylnicotinamide is an endogenous probe for evaluation of drug-drug interactions involving multidrug and toxin extrusions (MATE1 and MATE2-K)","volume":"92","author":"Ito","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.116.232066_bib25","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1124\/dmd.113.052290","article-title":"Substrate-dependent inhibition of organic anion transporting polypeptide 1B1: comparative analysis with prototypical probe substrates estradiol-17\u03b2-glucuronide, estrone-3-sulfate, and sulfobromophthalein","volume":"41","author":"Izumi","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.116.232066_bib26","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1124\/dmd.114.059105","article-title":"Investigation of the impact of substrate selection on in vitro organic anion transporting polypeptide 1B1 inhibition profiles for the prediction of drug-drug interactions","volume":"43","author":"Izumi","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.116.232066_bib27","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","article-title":"Impact of OATP transporters on pharmacokinetics","volume":"158","author":"Kalliokoski","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.116.232066_bib28","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/clinchem\/38.4.526","article-title":"Determining zinc coproporphyrin in maternal plasma\u2014a new method for diagnosing amniotic fluid embolism","volume":"38","author":"Kanayama","year":"1992","journal-title":"Clin Chem"},{"key":"10.1124\/jpet.116.232066_bib29","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/clpt.2008.132","article-title":"Cytochrome P450 induction by rifampicin in healthy subjects: determination using the Karolinska cocktail and the endogenous CYP3A4 marker 4\u03b2-hydroxycholesterol","volume":"84","author":"Kanebratt","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.116.232066_bib30","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1172\/JCI107113","article-title":"Coproporphyrin I and 3 excretion in bile and urine","volume":"51","author":"Kaplowitz","year":"1972","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.116.232066_bib31","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/bcp.12425","article-title":"Validation of 4\u03b2-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects","volume":"78","author":"Kasichayanula","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/jpet.116.232066_bib32","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11095-013-1144-y","article-title":"Investigation of endogenous compounds for assessing the drug interactions in the urinary excretion involving multidrug and toxin extrusion proteins","volume":"31","author":"Kato","year":"2014","journal-title":"Pharm Res"},{"key":"10.1124\/jpet.116.232066_bib33","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1136\/bmj.1.5488.652","article-title":"Urinary excretion of porphyrin precursors and coproporphyrin in healthy females on oral contraceptives","volume":"1","author":"Koskelo","year":"1966","journal-title":"BMJ"},{"key":"10.1124\/jpet.116.232066_bib34","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3109\/00365516609103918","article-title":"Separation of urinary coproporphyrin isomers 1 and 3 by thin-layer chromatography. Studies in healthy subjects and patients with myocardial infarction","volume":"18","author":"Koskelo","year":"1966","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1124\/jpet.116.232066_bib35","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/clinchem\/13.11.1006","article-title":"Urinary coproporphyrin isomer distribution in the Dubin-Johnson syndrome","volume":"13","author":"Koskelo","year":"1967","journal-title":"Clin Chem"},{"key":"10.1124\/jpet.116.232066_bib36","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/aps.2014.104","article-title":"Potential role of organic anion transporting polypeptide 1B1 (OATP1B1) in the selective hepatic uptake of hematoporphyrin monomethyl ether isomers","volume":"36","author":"Li","year":"2015","journal-title":"Acta Pharmacol Sin"},{"key":"10.1124\/jpet.116.232066_bib37","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/0007-0971(80)90079-0","article-title":"Rifampicin-induced porphyria cutanea tarda","volume":"74","author":"Millar","year":"1980","journal-title":"Br J Dis Chest"},{"key":"10.1124\/jpet.116.232066_bib38","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1023\/A:1007609225851","article-title":"Hepatic disposition of fexofenadine: influence of the transport inhibitors erythromycin and dibromosulphothalein","volume":"17","author":"Milne","year":"2000","journal-title":"Pharm Res"},{"key":"10.1124\/jpet.116.232066_bib39","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1124\/dmd.115.065946","article-title":"Rosuvastatin liver partitioning in cynomolgus monkeys: measurement in vivo and prediction using in vitro monkey hepatocyte uptake","volume":"43","author":"Morse","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.116.232066_bib40","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00228-014-1770-2","article-title":"N1-methylnicotinamide as an endogenous probe for drug interactions by renal cation transporters: studies on the metformin-trimethoprim interaction","volume":"71","author":"M\u00fcller","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/jpet.116.232066_bib61","series-title":"Guide for The Care and Use of Laboratory Animals","author":"National Research","year":"2011"},{"key":"10.1124\/jpet.116.232066_bib41","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.116.232066_bib42","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/pr.110.002857","article-title":"Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake","volume":"63","author":"Niemi","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1124\/jpet.116.232066_bib43","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.tox.2007.11.021","article-title":"The current state of serum biomarkers of hepatotoxicity","volume":"245","author":"Ozer","year":"2008","journal-title":"Toxicology"},{"key":"10.1124\/jpet.116.232066_bib44","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/sj.clpt.6100220","article-title":"Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin","volume":"82","author":"Pasanen","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.116.232066_bib45","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/bcp.12377","article-title":"Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin","volume":"78","author":"Prueksaritanont","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/jpet.116.232066_bib46","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1124\/jpet.114.221804","article-title":"Evaluation of rosuvastatin as an organic anion transporting polypeptide (OATP) probe substrate: in vitro transport and in vivo disposition in cynomolgus monkeys","volume":"353","author":"Shen","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.116.232066_bib47","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1124\/jpet.112.200691","article-title":"Cynomolgus monkey as a potential model to assess drug interactions involving hepatic organic anion transporting polypeptides: in vitro, in vivo, and in vitro-to-in vivo extrapolation","volume":"344","author":"Shen","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.116.232066_bib48","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/clpt.2013.128","article-title":"Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance","volume":"94","author":"Shin","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.116.232066_bib49","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/bdd.1823","article-title":"Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption","volume":"34","author":"Shitara","year":"2013","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/jpet.116.232066_bib50","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.1002\/jps.23477","article-title":"Long-lasting inhibitory effects of saquinavir and ritonavir on OATP1B1-mediated uptake","volume":"102","author":"Shitara","year":"2013","journal-title":"J Pharm Sci"},{"key":"10.1124\/jpet.116.232066_bib51","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.clpt.2004.03.010","article-title":"Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine","volume":"76","author":"Simonson","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.116.232066_bib52","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s10038-008-0324-9","article-title":"Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism","volume":"53","author":"Suwannakul","year":"2008","journal-title":"J Hum Genet"},{"key":"10.1124\/jpet.116.232066_bib54","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.2217\/pgs.14.155","article-title":"Detection of an endogenous urinary biomarker associated with CYP2D6 activity using global metabolomics","volume":"15","author":"Tay-Sontheimer","year":"2014","journal-title":"Pharmacogenomics"},{"key":"10.1124\/jpet.116.232066_bib55","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1086\/302292","article-title":"Genomic structure of the canalicular multispecific organic anion\u2013transporter gene (MRP2\/cMOAT) and mutations in the ATP-binding\u2013cassette region in Dubin-Johnson syndrome","volume":"64","author":"Toh","year":"1999","journal-title":"Am J Hum Genet"},{"key":"10.1124\/jpet.116.232066_bib56","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1172\/JCI59526","article-title":"Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver","volume":"122","author":"van de Steeg","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1124\/jpet.116.232066_bib58","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1124\/dmd.114.061051","article-title":"Utility of bilirubins and bile acids as endogenous biomarkers for the inhibition of hepatic transporters","volume":"43","author":"Watanabe","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.116.232066_bib59","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0002-9343(76)90426-5","article-title":"Rotor\u2019s syndrome. A distinct inheritable pathophysiologic entity","volume":"60","author":"Wolkoff","year":"1976","journal-title":"Am J Med"},{"key":"10.1124\/jpet.116.232066_bib60","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/clpt.2011.351","article-title":"Transporter-mediated drug\u2013drug interactions involving OATP substrates: predictions based on in vitro inhibition studies","volume":"91","author":"Yoshida","year":"2012","journal-title":"Clin Pharmacol Ther"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524193111?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524193111?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.116.232066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T19:45:06Z","timestamp":1739994306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524193111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0022356524193111"],"URL":"https:\/\/doi.org\/10.1124\/jpet.116.232066","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Coproporphyrins I and III as Functional Markers of OATP1B Activity: In Vitro and In Vivo Evaluation in Preclinical Species","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.116.232066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}